REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-RezLondon Stock Exchange·Jul 28 at 05:06 AMGSK-0.73%03692-2.42%
SHENGDA BIO-PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 53.34 million yuan, a year-on-year increase of 146.04%Zhitong·Oct 29, 2025 at 09:41 AM603079+4.67%
SHENGDA BIO-PHARM released its first-quarter performance, with a net profit attributable to the parent company of 21.7095 million yuan, a year-on-year increase of 469.35%Zhitong·Apr 27, 2025 at 03:04 AM603079+4.67%
Synthetic biology concept stocks strengthen, SHENGDA BIO-PHARM hits the daily limit in the afternoonZhitong·Apr 10, 2025 at 01:27 AM603079+4.67%301206+1.11%
SHENGDA BIO-PHARM: Wanjian Investment reduced its stake in the company by 1.36%Zhitong·Apr 6, 2025 at 02:40 AM603079+4.67%
SHENGDA BIO-PHARM and others established a technology company including retail business for publicationsZhitong·Mar 27, 2025 at 12:42 AM603079+4.67%
SHENGDA BIO-PHARM's private placement stock application has been approved for registration by the China Securities Regulatory CommissionZhitong·Feb 7, 2025 at 03:02 AM603079+4.67%
SHENGDA BIO-PHARM expects to turn a profit, with a projected net profit of 26 million to 36 million yuan in 2024Zhitong·Jan 20, 2025 at 03:13 AM603079+4.67%
SHENGDA BIO-PHARM's major shareholder WanJian Investment plans to reduce its holdings by no more than 3%Zhitong·Dec 27, 2024 at 06:22 AM603079+4.67%
